Biotech | January 20, 2026
DNA Nanorobots & AI could slash drug development times, Nanovery CEO says
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
The company has raised US$4.5 million in funding for its AI operating system
In 2030 over 50% of FDA approvals will involve AI discovered and developed drugs
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Alpenglow has created an end-to-end 3D spatial biology solution including patented high-throughput 3D imaging
Advancing to IND-enabling studies with multiple drug candidates
Subscribe To Our Newsletter & Stay Updated
